8-K: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

Terns Pharmaceuticals appoints Andrew Gengos as its new Chief Financial Officer, effective February 24, 2025.

Summary

• Terns Pharmaceuticals has appointed Andrew Gengos as Chief Financial Officer, effective February 24, 2025.
• Mr. Gengos brings 25 years of experience in the life sciences and biotechnology industry to the role.
• His previous roles include CFO at Athira Pharma, Chief Business Officer at Cyteir Therapeutics, and CEO positions at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals.
• Mr. Gengos will receive an annual base salary of $510,000 and is eligible for an annual cash bonus targeted at 40% of his base salary.
• He will also receive a stock option to purchase 750,000 shares of Terns common stock, vesting over four years.
• Amy Burroughs, the current CEO, will step down from her role as principal financial officer.
• David Strauss will continue to serve as Vice President of Finance and Controller.
• Mr. Gengos will act as both the principal financial officer and the principal accounting officer.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the appointment of an experienced CFO, which is generally viewed favorably by investors. However, the document also contains cautionary language regarding forward-looking statements, which tempers the overall sentiment.

Positives

• The appointment of Mr. Gengos brings a seasoned finance and corporate strategy executive with 25 years of experience to Terns.
• His experience includes taking a company public, which could be beneficial for Terns in the future.
• The compensation package includes a base salary, bonus potential, and stock options, aligning his interests with the company's success.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• The actual results of the company could vary materially from these forward-looking statements.
• The document references the company's SEC reports, including the Annual Report on Form 10-K, for a detailed discussion of risk factors.

Future Outlook

The company anticipates compelling clinical readouts from its lead oncology and obesity programs later this year.

Management Comments

• Amy Burroughs, CEO of Terns, stated that she is delighted to have Andrew join the team and is confident his experience will be instrumental in driving growth.
• Andrew Gengos stated that he is pleased to be joining Terns and looks forward to working with the team to build on the company's strong financial foundation.

Industry Context

The appointment of a seasoned CFO like Andrew Gengos is a common move for clinical-stage biopharmaceutical companies as they progress their pipeline and approach potential commercialization or partnership opportunities. His experience in taking a company public is particularly relevant in the current market environment.

Comparison to Industry Standards

• The compensation package for Mr. Gengos, including base salary, bonus target, and stock options, appears to be within the typical range for CFOs at publicly-traded biopharmaceutical companies of similar size and stage.
• Comparing to Athira Pharma, where Mr. Gengos previously served as CFO, the base salary is comparable, although the specific bonus and equity structures may differ based on company-specific factors.
• The vesting schedule of the stock options (25% after one year, then monthly over three years) is a standard vesting schedule in the industry.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively.
• Employees will have a new leader in the finance department.
• The appointment could impact the company's relationships with investors and analysts.

Next Steps

• Mr. Gengos will assume his responsibilities as CFO, focusing on financial leadership and supporting the company's growth.
• The company will continue to advance its oncology and obesity programs towards clinical readouts later this year.

Key Dates